Tempest Therapeutics awards director 25,000 options
The options vest over three years, with continued service required throughout the vesting period.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tempest Therapeutics, Inc. director Nancy Freda Smith received an award of options covering 25,000 common shares on September 22, 2026, with a $1 exercise price and an expiration date of September 22, 2036. The options vest over three years: one-third on the first anniversary of the grant date and the remainder in equal monthly installments thereafter, subject to her continued service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 25,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Key Figures
Key Terms
Stock option financial
Vesting financial
Exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options did TPST director Nancy Freda Smith receive?
What is the vesting schedule for the TPST option award?
AI-generated analysis. How Rhea-AI works. Not financial advice.